Bausch Health Companies Inc. last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $2.9 billion (+9.7% year over year) and diluted EPS of $1.15. It usually reports 13–29 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 12, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Jan 13, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 13–29 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
2,941
+9.7%
|
436
+143.6%
|
1.15
+139.6%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
2,852
+12.7%
|
258
+74.3%
|
0.68
+70.0%
|
|
Apr 29, 2026
29 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2,524
+11.7%
|
-1,423
-2353.4%
|
-3.82
-2287.5%
|
|
Jan 13, 2026
13 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
2,796
+9.3%
|
-112
-220.4%
|
-0.30
-217.6%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2,681
+6.8%
|
179
+310.6%
|
0.48
+308.7%
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2,530
+5.3%
|
148
+1380.0%
|
0.40
+1233.3%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2,259
+4.9%
|
-58
+9.4%
|
-0.16
+5.9%
|
|
Feb 19, 2025
50 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2,559
+6.3%
|
93
+338.5%
|
0.25
+336.6%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHC (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NJ
- Headquarters
- Quebec, Quebec, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 885590
- Former names
- Valeant Pharmaceuticals International, Inc. (until Jul 3, 2018); BIOVAIL Corp (until Sep 27, 2010); BIOVAIL CORP INTERNATIONAL (until Apr 7, 2010); BIOVAIL CORPORATION INTERNATIONAL (until Jan 5, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.